MedPath

Innovation Medical Management Co .,Ltd.

🇨🇳China
Ownership
-
Established
2003-09-30
Employees
36
Market Cap
-
Website
http://www.chxyl.com
Introduction

The company was founded in April 1997, completed its initial public offering of shares and listed on September 25, 2007. As the reform of the medical service industry continues to deepen, excellent private hospitals will achieve rapid development, and the profitability of target hospitals will continue to increase steadily in subsequent years. After the transaction is completed, the injection of high-quality assets will greatly enhance the profitability of listed companies, thereby maximizing shareholder value. The company is a listed company whose main business is providing medical services. Corporate honors: It won the third prize for the application of new medical and health technology at the provincial level in 2018, etc.

Topical Cyclosporine and Disease Progression

Phase 4
Completed
Conditions
Disease Progression
Disease Severity
Staining
Schirmers
OSDI
Interventions
First Posted Date
2007-12-05
Last Posted Date
2008-09-25
Lead Sponsor
Innovative Medical
Target Recruit Count
80
Registration Number
NCT00567983
Locations
🇺🇸

Lakeside Eye Clinic, Chicago, Illinois, United States

Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease

Phase 4
Completed
Conditions
Treatment of Dry Eye Disease
Interventions
Drug: Restasis, Refresh Plus
First Posted Date
2007-12-04
Last Posted Date
2010-07-30
Lead Sponsor
Innovative Medical
Target Recruit Count
40
Registration Number
NCT00567177
Locations
🇺🇸

Hermann Eye Center, 6400 Fannin Ste 1800, Texas, United States

Comfort and Cleaning Evaluation of Multipurpose Solutions in Contact Lens Patients

Phase 4
Completed
Conditions
Patient Comfort
Lens Cleanliness
First Posted Date
2007-08-23
Last Posted Date
2008-06-19
Lead Sponsor
Innovative Medical
Target Recruit Count
20
Registration Number
NCT00519948
Locations
🇺🇸

Eyeworks Group, Fort Worth, Texas, United States

Comfort Evaluation of a New MPS vs. Replenish in Contact Lens Patients

Phase 4
Completed
Conditions
Corneal Staining
First Posted Date
2007-08-21
Last Posted Date
2008-04-24
Lead Sponsor
Innovative Medical
Target Recruit Count
24
Registration Number
NCT00518700
Locations
🇺🇸

Private Practice, Azusa, California, United States

Cross-Over Evaluation of Two Lubricating Eye Drops

Phase 4
Completed
Conditions
Dry Eye
First Posted Date
2007-06-28
Last Posted Date
2008-01-15
Lead Sponsor
Innovative Medical
Registration Number
NCT00493662
Locations
🇺🇸

Hazleton Eye Specialists, Hazleton, Pennsylvania, United States

An Evaluation of Kinerase Pro+Therapy Regimen Vs. Kinerase Vs. Control for the Treatment of Skin Aging

Phase 4
Terminated
Conditions
Skin Aging
First Posted Date
2007-06-27
Last Posted Date
2007-12-24
Lead Sponsor
Innovative Medical
Registration Number
NCT00492479
Locations
🇺🇸

Steve Yoelin MD practice, Santa Ana, California, United States

Pilot Evaluation of Two Multipurpose Solutions in Regards to Corneal Staining

Phase 4
Completed
Conditions
Corneal Staining
First Posted Date
2007-06-07
Last Posted Date
2007-07-25
Lead Sponsor
Innovative Medical
Registration Number
NCT00483795
Locations
🇺🇸

Hazleton Eye Specialists, Hazleton, Pennsylvania, United States

Oasys vs. Extreme H20 Xtra 59

Phase 4
Completed
Conditions
Dry Eye
Interventions
First Posted Date
2007-05-24
Last Posted Date
2008-02-18
Lead Sponsor
Innovative Medical
Target Recruit Count
52
Registration Number
NCT00477763
Locations
🇺🇸

Hazleton Eye Specialists, Hazleton, Pennsylvania, United States

Pilot Study Evaluation of 2 Artificial Tears. Evaluation of TBUT, Tear Meniscus Height and Tear Thickness

Phase 4
Completed
Conditions
Tear Film Thickness
First Posted Date
2007-05-04
Last Posted Date
2007-09-10
Lead Sponsor
Innovative Medical
Registration Number
NCT00469521
Locations
🇺🇸

Magill Research Center Institute MUSC, Charleston, South Carolina, United States

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects

Phase 4
Completed
Conditions
Cataract
Interventions
Drug: Acular, Xibrom
First Posted Date
2007-05-04
Last Posted Date
2008-05-20
Lead Sponsor
Innovative Medical
Target Recruit Count
58
Registration Number
NCT00469690
Locations
🇺🇸

Bucci Laser Vision Institute and Ambulatory Surgery Center, Wilkes Barre, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath